MBX Biosciences, Inc. (MBX) Earnings Call Transcripts
MBX Biosciences, Inc.'s Latest Earnings Call - June 12, 2026
In the Q2 2026 earnings call for MBX Biosciences, the company reported significant progress with its once-weekly PTH replacement therapy, Canvuparatide, showing a 57% responder rate at one year, consistent with prior Phase II results. Revenue and earnings figures were not disclosed, but management emphasized that they have sufficient cash to fund operations into 2029, including the upcoming Phase III trial set to begin in Q3 2026. The company maintained its guidance for the Phase III study, reinforcing confidence in Canvuparatide's potential as a best-in-class treatment for chronic hypoparathyroidism.
Reported metrics
| Metric | Value |
|---|---|
| Responder Rate (1-Year) | 57% (inline) |
| Patient Retention Rate | 90% (positive) |
| Discontinuation Rate Due to Adverse Events | 5% (positive) |
| Cash Runway | Into 2029 (positive) |
| Dosing Range | 400 to 1,600 micrograms (positive) |
| Phase III Trial Start | Q3 2026 (positive) |
Guidance from management
Management maintained guidance for the Phase III trial, emphasizing that it is designed to confirm the efficacy and safety of Canvuparatide as a PTH replacement therapy.
What management said
Greetings, and welcome to the MBX Biosciences Business Update Call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Kent Hawryluk, President, CEO and Co-Founder of MBX Biosciences. Please go ahead, sir.
Well, thank you, Seamus. I'll just lead off briefly and pass it to Dr. Collins and then to Sam. Again, we're just really delighted with our 1-year data. We support the sustained clinical benefit and recall, this is really the first truly long-acting PTH therapy candidate. And our 1-year responder rate really was comparable to the 12-week Avail, which achieved as primary endpoint and to the once-daily ORV Phase II a...
What analysts pressed on
Analysts expressed concerns over the potential for compliance issues during the open-label extension, particularly regarding self-administration of the therapy. There were also inquiries about the increase in hypocalcemia rates during this period, which management attributed to dosing errors during home administration.
Main topics on the call
- Phase II Open-Label Extension Results — The one-year results from the open-label extension study demonstrated a 57% responder rate, indicating sustained efficacy of Canvuparatide. Management noted, "this data demonstrates sustained benefit of once weekly Canvu...
- Upcoming Phase III Trial — Management confirmed that the Phase III pivotal trial is on track to initiate in Q3 2026, with a randomized, double-blind, placebo-controlled design. They stated, "We have an exciting year ahead for MBX with several impo...
- Patient Retention and Satisfaction — The retention rate in the open-label extension was high at 90%, suggesting strong patient satisfaction with the treatment. CEO Kent Hawryluk remarked, "This really indicates satisfaction with once-weekly Canvuparatide."
- Safety Profile — The safety profile of Canvuparatide was consistent with expectations, with most adverse events being mild to moderate. Salomon Azoulay noted, "Only 5% of the patients discontinued the study due to treatment-emergent adve...
Read the full MBX Biosciences, Inc. transcript (June 12, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 30 calls on record spanning August 16, 2021 to June 12, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 30 MBX Biosciences, Inc. earnings call transcripts on record, spanning August 16, 2021 to June 12, 2026. Based on this history, MBX Biosciences, Inc. reports quarterly. The most recent call on file is dated June 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- MBX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 30
- First call
- August 16, 2021
- Most recent
- June 12, 2026
- Reporting cadence
- quarterly